WO2008031888A3 - Composé agissant sur les récepteurs glutamatergiques - Google Patents

Composé agissant sur les récepteurs glutamatergiques Download PDF

Info

Publication number
WO2008031888A3
WO2008031888A3 PCT/EP2007/059721 EP2007059721W WO2008031888A3 WO 2008031888 A3 WO2008031888 A3 WO 2008031888A3 EP 2007059721 W EP2007059721 W EP 2007059721W WO 2008031888 A3 WO2008031888 A3 WO 2008031888A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidinones
condensed
active
glutamatergic receptors
glutamatergic
Prior art date
Application number
PCT/EP2007/059721
Other languages
English (en)
Other versions
WO2008031888A2 (fr
Inventor
Giuseppe Campiani
Stefania Butini
Caterina Fattorusso
Sandra Gemma
Coccone Salvatore Sanna
Marianna Borriello
Original Assignee
Giuseppe Campiani
Stefania Butini
Caterina Fattorusso
Sandra Gemma
Coccone Salvatore Sanna
Marianna Borriello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuseppe Campiani, Stefania Butini, Caterina Fattorusso, Sandra Gemma, Coccone Salvatore Sanna, Marianna Borriello filed Critical Giuseppe Campiani
Publication of WO2008031888A2 publication Critical patent/WO2008031888A2/fr
Publication of WO2008031888A3 publication Critical patent/WO2008031888A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I), un procédé de préparation de celui-ci et les utilisations de celui-ci.
PCT/EP2007/059721 2006-09-15 2007-09-14 Composé agissant sur les récepteurs glutamatergiques WO2008031888A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2006A000491 2006-09-15
IT000491A ITRM20060491A1 (it) 2006-09-15 2006-09-15 Composti attivi sui recetori glutammatergici

Publications (2)

Publication Number Publication Date
WO2008031888A2 WO2008031888A2 (fr) 2008-03-20
WO2008031888A3 true WO2008031888A3 (fr) 2008-12-18

Family

ID=39092726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/059721 WO2008031888A2 (fr) 2006-09-15 2007-09-14 Composé agissant sur les récepteurs glutamatergiques

Country Status (2)

Country Link
IT (1) ITRM20060491A1 (fr)
WO (1) WO2008031888A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003881A1 (fr) * 2013-07-08 2015-01-15 Syngenta Participations Ag Dérivés hétérobicycliques microbiocides
US9809602B2 (en) 2014-04-17 2017-11-07 Institut Pasteur Korea Compounds for treating viral infections
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0884316A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA
EP0884310A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazolin-4-ones comme antagonistes de récepteur AMPA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0884316A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA
EP0884310A1 (fr) * 1997-06-09 1998-12-16 Pfizer Products Inc. Quinazolin-4-ones comme antagonistes de récepteur AMPA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIUSEPPE CAMPIANI ET AL.: "1-H-cyclopentapyrimidine-2,4(1H,3H)-dione Derivative (S)-CPW399 as a novel,Potent, and Subtype-selective AMPA Receptor Full Agonist with Partial Desensitization Properties", JOURNAL OF MEDICINAL CHEMISTRY., vol. 44, no. 26, 17 November 2001 (2001-11-17), USAMERICAN CHEMICAL SOCIETY., pages 4501 - 4504, XP002486751 *
KOTAKE Y ET AL: "SYNTHESIS AND ANTITUMOR ACTIVITIES OF NOVEL 6-5 FUSED RING HETEROCYCLE ANTIFOLATES: N-Ä4ÄOMEGA-(2-AMINO-4-SUBSTITUTED-6,7- DIHYDROCYCLOPENTAÄDÜPYRIMIDIN-5-YL)ALKYLÜBENZOYLÜ-L-GLUTAMIC ACIDS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 37, no. 11, 1 January 1994 (1994-01-01), pages 1616 - 1624, XP002927773, ISSN: 0022-2623 *
LEES G J: "PHARMACOLOGY OF AMPA/KAINATE RECEPTOR LIGANDS AND THEIR THERAPEUTIC POTENTIAL IN NEUROLOGICAL AND PSYCHIATRIC DISORDERS", DRUGS, ADIS INTERNATIONAL LTD, vol. 59, no. 1, 1 January 2000 (2000-01-01), pages 33 - 78, XP009043409, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
WO2008031888A2 (fr) 2008-03-20
ITRM20060491A1 (it) 2008-03-16

Similar Documents

Publication Publication Date Title
WO2006087143A8 (fr) Nouveaux procedes de preparation d'un 2h-chromene
CA2661102C (fr) Derives du thiophene comme agonistes du recepteur s1p1/edg1
WO2008083248A3 (fr) Analogues de cyclopamine
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2009057079A3 (fr) Nouveaux dérivés de pyrimidine
WO2009156462A3 (fr) Composés organiques
WO2006100635A3 (fr) Nouveaux derives de thiophene
WO2009074950A3 (fr) Nouveaux dérivés du thiophène
WO2006053255A3 (fr) Nouveaux derives de betuline, preparation de ces derives et utilisation de ces derives
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007127292A3 (fr) Formes cristallines de tigecycline et leurs procedes de preparation
WO2007030361A3 (fr) Composes de benzimidazole thiophene
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2008149345A3 (fr) Composés triarylés et compositions les comprenant
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
WO2008083130A3 (fr) Compositions à base de carvédilol
WO2009040314A3 (fr) Nouveaux dérivés de l'acétone substitués par un hétéroaryle, appropriés comme inhibiteurs de la phospholipase a2
WO2009002538A3 (fr) Erlotinib amorphe, procédés d'élaboration de l'erlotinib, et procédés d'élaboration d'autres formes d'erlotinib
WO2008033757A3 (fr) Dérivés d'acétamide 2-(1-oxo-1h-isoquinolin-2-yl)
WO2007061948A3 (fr) Modulateurs de cannabinoides 5-heteroaryl-1-phenyl-pyrazoliques substitues
WO2006128802A3 (fr) 3-methanesulfonylquinolines renforçant le gaba-b
WO2008153902A3 (fr) Antagonistes des récepteurs de l'urotensine ii
WO2008031888A3 (fr) Composé agissant sur les récepteurs glutamatergiques
WO2008019030A8 (fr) Composés d'azole modifiés en tant qu'agents anti-infectieux
WO2008146883A1 (fr) Agent d'amélioration du sommeil

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07820225

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07820225

Country of ref document: EP

Kind code of ref document: A2